TPO-RA ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
63	Idiopathic thrombocytopenic purpura	2

63. Idiopathic thrombocytopenic purpura

---

Clinical trials : 391 /  Drugs : 235 - (DrugBank : 50) / Drug target genes : 49 - Drug target pathways : 139

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05718856 (ClinicalTrials.gov)	April 1, 2023	13/11/2022	TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)	A Multicenter, Randomized, Open-label StudyTo Compare The Efficacy And Safety Of TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in Persistent or Chronic Pediatric ITP Patients Who Failed or Relapse After Hormone Therapy	Primary Immune Thrombocytopenia (ITP)	Drug: TPO-RAs;Drug: TPO-RAs combining anti-CD 20 monoclonal antibody	Institute of Hematology & Blood Diseases Hospital	Beijing Children's Hospital;Tianjin People's Hospital;The Second Affiliated Hospital of Kunming Medical University;Henan Cancer Hospital;Tianjin Medical University Second Hospital;The First Affiliated Hospital of Xiamen University	Not yet recruiting	6 Years	17 Years	All	166	Phase 4	China
2	NCT04890041 (ClinicalTrials.gov)	May 30, 2021	12/5/2021	TPO-RA in Primary Immune Thrombocytopenia (ITP) in Patients Older Than 14 Years	Efficacy of TPO-RA in the Management of Primary Immune Thrombocytopenia (ITP) in Patients Older Than 14 Years With Poor First-line Response: a Multi-center, Prospective, One-arm Study	Primary Immune Thrombocytopenic Purpura	Drug: TPO-RA	Institute of Hematology & Blood Diseases Hospital	NULL	Recruiting	14 Years	N/A	All	100	N/A	China